The terminal-native browser verification tool ships today with native support for Claude Code, Codex CLI, Cursor, and Gemini CLI, and it’s free to start

SAN FRANCISCO and NOIDA, India, April 29, 2026 /PRNewswire/ — TestMu AI (formerly LambdaTest), the world’s first full-stack Agentic Quality Engineering platform, today announced the launch of Kane CLI, a new browser automation tool that runs directly from the terminal. Kane CLI is the first tool designed simultaneously for human developers and AI coding agents, closing the gap between code generation and verified browser execution.

AI coding agents have transformed how software gets written, as AI agents are shipping code faster than any QA team can click through flows manually. Features ship from prompts. Bugs get fixed in seconds. But the development loop has never fully closed: no agent can open a browser and verify that what it built actually works. That step still falls to a human. Kane CLI is built to close this loop.

Teams build features, spot bugs, ship code, and run agents. Kane CLI is the verification layer for all of it. Developers and QA engineers describe the flow and get pass or fail with a full step trace and screenshot before the PR goes up. Designers and PMs verify fixes and broken flows without filing a ticket or waiting for a developer, then drop the shareable evidence link straight into Slack or Jira.

AI agents like Claude Code, Codex CLI, Cursor, and Gemini CLI build a feature; Kane CLI is the missing tool that tells them whether it actually works in the local Chrome browser.

Key Capabilities of Kane CLI include:

• Intent-based browser control: Operates purely on intent, requiring no selectors or underlying code.
• Resilient runs: Kane CLI does not return halfway. It adapts and pushes through, up to 50 steps per flow, until the full journey is verified. Other tools break on the first change. Kane CLI finishes the run.
• Playwright export: Converts plain English test flows into native Playwright test code with one command.
• Automated bug discovery: Actively monitors and surfaces unexpected behaviors while the test flow is running.
• Vision-based dynamic waiting: Detects loaders and animations on screen before acting. Not network-based. Handles canvas, Shadow DOM, and element frameworks that cannot be resolved.
• Ask the tool for OTPs and CAPTCHAs: When an automated flow hits an OTP screen or a CAPTCHA, it does not fail silently. Kane CLI pauses, asks the human to handle that one step, and then continues the run. For AI agents, this is human-in-the-loop without stopping the entire workflow.
• Two-way script migration: Convert existing Playwright or Selenium scripts to Kane CLI. Convert Kane CLI tests back to Playwright. No rewrite from scratch.
• Inbuilt Test Manager sync: Every test case created locally is also saved remotely. Shareable proof attached automatically.
• CI/CD ready: Runs headlessly in GitHub Actions, GitLab CI, Jenkins, and Bitbucket Pipelines. Standard exit codes plug into pipeline control flow without any custom scripting.
• Contextual authoring: Give Kane CLI context about your app, and it authors parallel test cases across multiple browser sessions from a single prompt.

Three Ways to Run

Kane CLI ships with three modes so humans and agents can consume it the same way from the same terminal.

• Interactive TUI – No arguments needed. A full terminal UI opens for exploring, iterating, and chaining tests across a live browser session.
• Headless CLI – Add –headless for scriptable, display-free runs. Built for shell scripts and CI pipelines.
• Agent Mode – Add –agent –headless. Outputs structured NDJSON that Claude Code, Codex CLI, and Gemini CLI read natively to decide what to do next.

Asad Khan, CEO & Co-Founder, TestMu AI, said, “For years, the bottleneck in software was writing the code. Vibe coding removed that. Teams are shipping more software, faster, than at any point in the history of our industry. But it exposed a new bottleneck most teams haven’t named yet: trust. Every feature that ships from a prompt is a feature nobody has actually verified. At agentic speed, ‘a human will click through it later’ is not a plan — it’s a liability, compounding at the speed of AI. It’s a growing pile of unverified work. That’s why we built Kane CLI. One terminal command, a real browser, pass or fail. Software has always trusted the people who wrote it. Now, for the first time, it has to trust the machines. Kane CLI is how trust scales in the agentic era.”

As part of its launch, TestMu AI is offering bonus credits for the first three months to teams that activate a paid plan during the introductory period. The offer is designed to give engineering and quality teams full access to Kane CLI’s cloud capabilities.

Kane CLI is available today, free to start. Install via npm or brew, log in, and run your first flow.

Installation command for Kane CLI via npm – npm install -g @testmuai/kane-cli

Installation command for Kane CLI via Homebrew – brew install LambdaTest/kane/kane-cli

Or building with an AI agent? Point it to testmuai.com/kane-cli/agents.md

For a quick start, visit the docs at testmuai.com/support/docs/kane-cli-introduction/ and to learn more, visit testmuai.com/kane-cli

About TestMu AI (Formerly LambdaTest)

TestMu AI is the world’s first Agentic AI-powered Quality Engineering platform, designed to enable organizations to automate and scale testing with intelligence at its core. By combining autonomous capabilities with seamless integration across modern development workflows, TestMu AI empowers teams to deliver faster, more reliable, and secure software in an AI-first world.

For more information, visit https://www.testmuai.com/

TAIPEI and TAICHUNG, April 29, 2026 /PRNewswire/ — A 38-year-old Hong Kong woman has successfully achieved pregnancy and “graduated” from her fertility journey after four previous failed IVF attempts in Hong Kong. The breakthrough came under the care of Dr. Cheng-Hsuan Wu, Vice Director of NUWA Fertility Center in Taichung, whose medical intervention identified a long-overlooked case of chronic endometritis and utilized advanced PGT-A and ERA screening technologies to ensure a successful embryo transfer.

Chronic Endometritis: The Hidden Culprit Behind Recurrent Implantation Failure

Upon her initial arrival at the clinic, the patient was disheartened, believing this was her final opportunity. Following a thorough hysteroscopy, Dr. Wu identified Chronic Endometritis as the critical cause of her past failures. Dr. Wu explained that chronic inflammation of the uterine lining alters the micro-environment, making it difficult for embryos to implant—a hidden factor frequently overlooked in cases of recurrent implantation failure.

Dr. Wu further noted that according to medical literature, approximately 30% of habitual miscarriages and recurrent failures are caused by chronic endometritis. For this patient, a two-week course of antibiotic treatment was administered to resolve the inflammation before officially commencing the IVF cycle.

Cutting-Edge Technology: PGT-A and ERA Identify the “Golden Window” for Implantation

To maximize the success rate of a single transfer for a patient with multiple previous failures, Dr. Wu utilized two key technologies:

• PGT-A (Preimplantation Genetic Testing for Aneuploidy): Ideal for advanced maternal age or those with recurrent miscarriages. By screening for embryos with the correct number of chromosomes, PGT-A significantly reduces miscarriage rates and boosts the pregnancy rate per transfer.

• ERA (Endometrial Receptivity Analysis): Every woman has a unique “window of implantation”. Approximately 30% of women have a window that differs from the standard timing. ERA uses genetic testing to calculate the precise hour for transfer, ensuring the embryo is introduced when the uterine lining is at its most receptive state.

By combining high-quality embryos screened via PGT-A with the precise timing determined by ERA, Dr. Wu carefully transferred a healthy embryo, resulting in an immediate pregnancy for the patient who had nearly given up hope.

Taiwanese Reproductive Medicine: A Top Choice in Asia

Dr. Wu observed a significant increase in patients traveling to Taiwan from Hong Kong, Macau, Japan, Southeast Asia, Europe, and the U.S. for egg freezing, IVF, or donor egg programs. He highlighted three primary reasons for this trend:

1. Technical Success Rates: Taiwan’s IVF success rate is ranked second in the world, following only the United States. NUWA Healthcare features high-specification laboratories and professional embryologists, supported by precision monitoring systems that ensure treatment stability.
2. Cost Competitiveness: The cost of IVF and egg freezing in Taiwan is approximately one-third of the prices in the U.S. and Hong Kong, offering world-class medical services at a more accessible price point.
3. Comprehensive Medical Support: With frequent flights between Hong Kong and Taiwan and multi-language support, NUWA Healthcare offers a seamless experience. The clinic provides online consultations and flexible weekend appointments, significantly reducing the temporal and psychological burden on international patients.

“Witnessing the transformation of a patient’s despair into the joy of pregnancy not only fulfills a family’s dream but also proves the technical prowess and compassionate care of Taiwan’s medical sector on the international stage,” Dr. Wu emphasized.

For more international success stories from NUWA Healthcare:
https://www.nuwacare.com/zh-TW/stories/intl-Healthcare-Center/1

Information on IVF and Egg Freezing Seminars:
https://www.nuwacare.com/zh-TW/news/seminars/1

Comparison Guide: IVF in Hong Kong vs. Taiwan:
https://www.nuwacare.com/zh-TW/health-education/hongkong-taiwan-ivf-price

CHICAGO, April 29, 2026 /PRNewswire/ — As artificial intelligence continues to scale globally, the infrastructure supporting it is undergoing rapid transformation. Increasing compute density is driving higher thermal loads in data centers, while rising electricity demand is placing growing pressure on power transmission and distribution systems. In this evolving landscape, material performance has become a key factor in enabling efficiency, reliability, and scalability.

bedra, a global manufacturer of precision copper alloys, addresses these challenges with a portfolio of high-performance materials engineered for AI-related applications. At IEEE PES T&D 2026, the company will present its latest innovations, represented on site by its Vietnam-based subsidiary. The following two application areas highlight how bedra’s materials support the development of AI.

Enabling High-Density AI Computing Systems

Within AI data centers, rising rack-level power density is accelerating the adoption of liquid cooling. bedra’s high-purity copper materials serve as critical components for liquid cooling plates, enabling efficient heat dissipation at hotspot including GPU and CPU. Powerway high-performance copper alloys feature exceptional resistance to high-temperature softening. With post-brazing strength exceeding pure copper by >30%, they ensure structural integrity, enabling the miniaturization of next-generation liquid cooling components.

Our oxygen-free copper, with electrical conductivity of up to 101% IACS, bedra’s copper alloys support efficient power delivery within data centers by reducing voltage drop and minimizing energy loss under high-current conditions. Their excellent formability enables compact electrical cabinet designs, while tight dimensional tolerances for rack-level busbars ensure full compatibility with OCP standards. Moreover, Optional silver and tin plating further extend application performance.

Supporting Power Infrastructure for AI Expansion

Beyond data centers, AI growth is increasing demand for reliable power infrastructure. Medium- and high-voltage systems operate under extreme conditions, making material performance essential for long-term stability.

bedra offers a range of engineered copper alloys. Materials such as bedra18200, Cu-Cr precipitation-strengthened alloy, has about 75% of pure copper’s conductivity but significantly higher strength and hardness.With very good resistance to softening, wear, and deformation at high temperatures, it’s quite suitable for stationary contacts, contact stems, contact bases, and other current-carrying structural members. For some demanding high-voltage environments, bedra18150(Cu-Cr-Zr) offers upgraded performance with improved creep resistance and enhanced high-temperature stability. This ensures reliable electrical performance, minimal wear, and extended service life. bedra10100, Cu-OFE Oxygen-Free-Electronic Copper, is ideal for high-reliability parts in HV vacuum interrupters, minimizing energy losses and improving dielectric performance.

Empowering Global Supply with Scalable Production

Our modern production facility in Vietnam underpins bedra’s global supply chain with large-scale, reliable manufacturing capabilities. Boasting an annual production capacity of 50,000 tons and holds ISO9001, ISO14001, ISO45001 and IATF16949 certifications, bedra provides over 400 copper, brass, bronze and nickel silver alloy grades,plus customized special profiles.

Sustainability is integral to bedra’s operations. Recognized with an EcoVadis Bronze Medal and CDP Grade B, we maintain a diversified, low-carbon energy mix to support responsible material production for critical power infrastructure worldwide.

Visitors to IEEE PES T&D 2026 can meet bedra at Booth 4885 to learn more.

MUMBAI, India, April 29, 2026 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full-year ended 31^st March 2026.

1. During the quarter, the management has recognized an impairment loss of ₹. 176Cr in relation to intangible assets under development. Based on a reassessment incorporating changes in market conditions and updated commercial viability estimates, management concluded that the probable future economic benefits from the asset are no longer expected to be adequate to justify further capital deployment.  Accordingly, the carrying amount has been written down in full.

Key Highlights

• Revenue – Growth was impacted by inventory destocking, slower early-stage order inflows in H1FY26, and softer traction in inhalation anesthesia across ex‑US markets. Adjusted for inventory destocking, we delivered YoY growth in Q4 and FY26.
• EBITDA Margin – Despite lower revenues, impact on EBITDA was partly offset by our efforts towards cost optimization and operational excellence.
• Capex – US$94Mn invested in FY26 across growth and maintenance projects. Lexington and Riverview expansions on track. Seeing good customer interest.
• Net Debt – No increase over FY25.

Nandini Piramal, Chairperson, Piramal Pharma Limited said, “FY26 was a transitional year, shaped by external disruptions and certain business-specific factors. Despite these challenges, we exited the year on a stronger note, with clear momentum across all our businesses. The meaningful recovery in biopharma funding seen from Sep’25,  is translating into good RFP momentum and healthy pick up in order inflows in our  CDMO business. In the CHG business, the recently completed Kenalog® acquisition alongside ramp up of inhalation anesthesia sales in ex-US markets are expected to be key growth drivers. Our Consumer Healthcare business is also well positioned to sustain its growth momentum with margin improvement driven by Power Brands and rapid growth in e‑commerce.

Overall, all three businesses are well positioned to deliver growth in FY27, accompanied by accelerated growth in EBITDA and PAT.”

Key Business Highlights

Contract Development and Manufacturing Organization (CDMO):

• Healthy traction in RFPs and order inflows in H2FY26 driven by stronger US biopharma funding (up YoY 75% in H2FY26, 30% in FY26) and M&A activity. (Industry Source)
• Overseas sites seeing rising demand from shifting customer geographical preferences and strong growth in differentiated areas such as ADC, HP API, on‑shore injectables and drug product capabilities.
• US$90Mn Capex on track to scale sterile injectable and payload-linker capacities at Lexington and Riverview sites.
• Net Promoter Score of 60 – surpassing industry average. Meaningful improvement in execution with stronger performance across key operational matrices, driven by our operational excellence initiatives.
• 209 customer site audits in FY26 vs. 165 in FY25 — highest ever. Reflecting heightened customer engagement, deeper technical interactions, and the growing complexity of programs we support.
• Maintained our Best-in-Class Quality Track Record – Successfully closed 38 regulatory inspections, including 3 USFDA inspections in FY26. Continue to maintain our ‘Zero OAI’ status.

Complex Hospital Generics (CHG):

• Completed Kenalog® acquisition

  – Upfront consideration of US$35Mn, and contingent consideration of up to US$65Mn.
  – Broadens CHG portfolio, adds revenues with minimal incremental cost, and expands presence in US, Europe & Asia Pacific.
  – Niche brand with complex manufacturing process. EBITDA margins in line with CHG business.

• Inhalation Anesthesia (IA) 

  – Continue to maintain leadership with 47% market share – up from 45% in Mar’24. (Source:- IQVIA)
  – Initiated Sevoflurane supplies from lower cost Digwal facility in select RoW markets. Expect traction to build going ahead.

• Intrathecal Therapy – Maintained our #1 Rank in intrathecal Baclofen segment in the US. (Source:- IQVIA)
• Injectable Pain Management – Continue to work with our supplier to resolve supply constraints.

Piramal Consumer Healthcare (PCH):

• Power Brands continued growth momentum with 24% YoY growth in FY26, contributing 52% to PCH sales. Little’s, Lacto Calamine, CIR, and i-range remained primary driver of growth.
• New Product Launches – Fewer, high‑potential product launches with better success rates. Launched 31 new products and SKU in FY26. Focus on premiumization of portfolio.
• E-commerce sales grew at 48% rate YoY in FY26, contributing about 27% to PCH sales. Evolve product mix toward premium offerings and high margin channel (e.g. quick commerce).
• Invested about 12% of PCH sales on Media and Trade Promotion in FY26. Optimizing the media mix – Social Media, Television, Influencers, etc.

1. During the quarter, the management has recognized an impairment loss of Rs. 176Cr in relation to intangible assets under development. Based on a reassessment incorporating changes in market conditions and updated commercial viability estimates, management concluded that the probable future economic benefits from the asset are no longer expected to be adequate to justify further capital deployment.  Accordingly, the carrying amount has been written down in full.

2. IAUD – Intangible Assets Under Development; 3. Other Assets include Investments and Deferred Tax Assets (Net)

Earnings Conference Call

Piramal Pharma Limited will be hosting a conference call for investors / analysts on 29^th April 2026 from 9:30 AM to 10:15 AM (IST) to discuss its Q4 and full-year FY26 Results.

The dial-in details for the call are as under:

About Piramal Pharma Limited:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17¹ global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and Piramal Consumer Healthcare (PCH) business, selling over-the-counter consumer and wellness products. In addition, one of PPL’s associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

For more information, visit:  Piramal Pharma | LinkedIn

1. Includes one facility via PPL’s minority investment in Yapan Bio.

Logo – https://laotiantimes.com/wp-content/uploads/2026/04/piramal_pharma_limited_logo.jpg

NINGBO, China, April 9, 2026 /PRNewswire/ — The Shanghai Cooperation Organization’s (SCO) Green and Sustainable Development Forum was held in Ningbo, Zhejiang province, April 28–30. At this international event focused on green, low–carbon transition, Ningbo showcased concrete examples of harmonious coexistence between people and nature.

Meishan Port — Zhejiang’s first “Green Power Terminal” and a global benchmark for green porttransformation — reduces carbon emissions by about 15,000 tons annually.

An abandoned quarry has been converted into an international racetrack, whose engine roars have stimulated a growing cultural and tourism sector. A once–barren “firewood trail” has been upgraded into a national mountaineering route, spawning distinctive local industries now known as the “Hometown of China’s Sports Walking Sticks” and the “Capital of China’s Flashlights.” Ningbo continues to advance its “Eco+” integration model, turning ecological assets into industrial momentum, development potential and measurable gains in shared prosperity. The city has developed a practical path for realizing the value of lucid waters and lush mountains, offering a replicable “Ningbo model” for green, low–carbon urban transformation worldwide.

In Beilun, more than 500 species have been recorded, and the district has been designated a UN “Biodiversity Charming City.” From the revitalized Meishan Bay in Beilun to the misty expanse of Dongqian Lake in Yinzhou and the historic allure of Moon Lake in Haishu, local authorities are using the “golden key” of ecological governance to revive dormant green mountains and clear waters. Notably, Ningbo’s ecological governance goes beyond mountain repair and water treatment: it integrates “Eco+” development from the source through unified planning and coordinated implementation—protecting ecological foundations while preserving space for industry. This forward–looking approach has produced a win–win outcome for ecology and development; along Meishan Bay’s shore, cultural tourism and leisure industries have rapidly clustered, receiving more than 2 million visitors annually.

In Fenghua, the “Common Prosperity Studio” initiative has built a full–chain platform integrating “5G + IoT + Agriculture,” and introduced a model that combines village–collective fixed–rent leasing, professional enterprise operation and flexible farmer participation. In Yuyao, Hemudu pioneered China’s first ecological integrated farming of breeding soft–shelled turtles in water oat fields, balancing ecological protection, food security and farmers’ income growth. Zhenhai Refining & Chemical has established China’s first “Zero–Waste Petrochemical Base,” recognized as a national model case of a “Zero–Waste Industrial Park.”

Leveraging its mountain and sea resources, Ningbo has deepened chain–based integration of “Ecology + Cultural Tourism + Sports + Manufacturing,” continuously converting ecological value into tangible benefits for residents. Ninghai has transformed abandoned ancient paths into a 500–km national mountaineering trail and established a national sports–industry demonstration base. Xiangshan has used the Asian Games to invigorate coastal tourism and open channels for converting marine ecological value. Yinzhou and Haishu have developed biodiversity–friendly districts and townships, fostering new sectors such as educational tourism and cultural–creative industries.

To ensure green development proceeds steadily and sustainably, Ningbo is building a multi–stakeholder governance system that includes government, enterprises and the public. Ninghai has pioneered a “Soil and Forestland Bank,” using financial instruments to unlock the value of forestry resources. Yinzhou, Cixi and other areas have mobilized broad public participation in ecological protection, creating a co–construction and shared–benefits model that supports ongoing ecological value realization.

The flagship lineup introduces the world’s first Dual Intelligent Iris System and delivers cinematic 4K performance designed for large-format home entertainment.

NEW YORK, April 29, 2026 /PRNewswire/ — XGIMI, a global leader in premium smart projection and home entertainment, today announced that its flagship TITAN Noir Series 4K projectors have surpassed $10 million in crowdfunding on Kickstarter since open orders from April 23, marking a major milestone for the company’s most advanced projector lineup to date.

Since launching yesterday, the campaign has attracted support from more than 3000 backers worldwide, highlighting strong early demand for premium projection solutions capable of delivering cinema-quality performance at home.

The TITAN Noir Series represents XGIMI’s most advanced engineering to date, developed for home theater enthusiasts seeking uncompromising image performance across large viewing surfaces for gaming, live sports and enjoyment. Central to the lineup is the world’s first Dual Intelligent Iris System, designed to dynamically optimize light control and deliver up to 10,000:1 native contrast for deeper blacks, enhanced highlights, and lifelike shadow detail.

“This level of early support reflects the growing importance consumers are placing on image quality and viewing scale when it comes to home entertainment,” said Apollo Zhong, Founder and CEO at XGIMI. “The TITAN Noir Series was developed to address the needs of viewers who expect exceptional contrast accuracy, brightness, and clarity across large-format displays. This momentum reinforces the direction we’re taking as we continue advancing projection technology.”

Engineered for Cinematic Precision

The TITAN Noir Series launched on Kickstarter with three models – TITAN Noir Max, TITAN Noir Pro, and TITAN Noir – each designed to support different performance needs while maintaining a consistent focus on cinematic image quality and precision engineering.

The lineup offers flexible performance tiers designed to support a range of home cinema environments. All three models are now available for order, with introductory pricing as follows:

• TITAN Noir Max: $2,999 (MSRP $5,999)
• TITAN Noir Pro: $2,699 (MSRP $4,999)
• TITAN Noir: $2,499 (MSRP $3,999)

To celebrate and reward backer support, XGIMI has introduced the following milestone gifts, which will be unlocked as the campaign progresses:

• $10M – Unlocked
  All backers will receive 2 x XGIMI Active Shutter 3D Glasses
• $15M – Next Goal
• $20M – Final Goal

The TITAN Noir Series Kickstarter campaign will remain live until June 9th, 2026, with shipping also beginning in June. XGIMI is also offering exclusive launch pricing on select accessories, allowing backers to customize and optimize their home cinema or living room setups.

For more information, visit the official XGIMI TITAN Noir Series Kickstarter page or XGIMI.com.

About XGIMI

Since 2013, the state-of-the-art XGIMI projectors have helped countless people worldwide to create genuinely immersive audio-visual experiences. Working with reputable partners like Google, Harman Kardon, and Texas Instruments, XGIMI builds all-in-one entertainment devices, perfected due to their user-oriented philosophy. Through industry-leading innovation, streamlined setups, and unique designs, XGIMI always strives to develop the best home and portable projectors for everyone to enjoy. XGIMI is also expanding their expertise into commercial projector technology to bring immersive experiences to more spaces. Learn more at XGIMI Projector Technology.